tbuckley/cabot-search huggingface dataset:
Abstract P3-12-04: Extending therapy after 5-year adjuvant hormone therapy in breast cancer patients: A population-based study
Authors: Erwei Zeng, Wei He, Jenny Bergqvist, Kamila Czence
Journal: Cancer Research (2022)

Abstract Background: Clinical guidelines have recommended breast cancer patients with certain characteristics to extend their therapy after 5-year adjuvant hormone therapy. However, no study thus far has described the prevalence, predictors, and outcomes of extending adjuvant hormone therapy in the real world. Methods: We identified 2,937 breast cancer patients who completed 5-year adjuvant hormone therapy during 2010-2019 in Stockholm, Sweden, by linking the Quality Register for Breast Cancer, Prescribed Drug Register, and Cause-of-death Register. We followed them until September 2020. Extended adjuvant hormone therapy was defined as having at least 2 prescriptions of tamoxifen and/or aromatase inhibitors after completing 5-year therapy. We used logistic regression to examine predictors of extended adjuvant hormone therapy and Cox regression to examine whether extended therapy is associated with distant metastasis-free survival, disease-free survival and all-cause mortality. Results: The proportion of extending therapy after 5-year adjuvant hormone therapy increased by 7 times during the past decade, from 8.8% in 2010 to 63.7% in 2019. Predictors of extended adjuvant hormone therapy included young age (≤50 years) at extension, positive lymph node status, high tumor grade and chemotherapy, among which chemotherapy was the strongest predictors [adjusted hazard ratio (HR), 4.64 (95% CI, 3.64-5.92)]. Among patients with chemotherapy, extended therapy improved distant metastasis-free survival [adjusted HR, 0.34 (95 CI%, 0.15-0.78)] and disease-free survival [adjusted HR, 0.61 (95 CI%, 0.39-0.95)]. Therapy discontinuation rates were similar during the first and second five years. Conclusion: Increasing number of breast cancer patients are extending adjuvant hormone therapy, even among patients without clear recommendations in clinical guidelines. Our findings support extended adjuvant hormone therapy in breast cancer patients with chemotherapy. Citation Format: Erwei Zeng, Wei He, Jenny Bergqvist, Kamila Czence. Extending therapy after 5-year adjuvant hormone therapy in breast cancer patients: A population-based study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-12-04.
Modern developments in germline pharmacogenomics for oncology prescribing
Authors: Natalie M. Reizine, Peter H. O’Donnell
Journal: CA A Cancer Journal for Clinicians (2022)

Abstract The integration of genomic data into personalized treatment planning has revolutionized oncology care. Despite this, patients with cancer remain vulnerable to high rates of adverse drug events and medication inefficacy, affecting prognosis and quality of life. Pharmacogenomics is a field seeking to identify germline genetic variants that contribute to an individual's unique drug response. Although there is widespread integration of genomic information in oncology, somatic platforms, rather than germline biomarkers, have dominated the attention of cancer providers. Patients with cancer potentially stand to benefit from improved integration of both somatic and germline genomic information, especially because the latter may complement treatment planning by informing toxicity risk for drugs with treatment‐limiting tolerabilities and narrow therapeutic indices. Although certain germline pharmacogenes, such as TPMT , UGT1A1 , and DPYD , have been recognized for decades, recent attention has illuminated modern potential dosing implications for a whole new set of anticancer agents, including targeted therapies and antibody‐drug conjugates, as well as the discovery of additional genetic variants and newly relevant pharmacogenes. Some of this information has risen to the level of directing clinical action, with US Food and Drug Administration label guidance and recommendations by international societies and governing bodies. This review is focused on key new pharmacogenomic evidence and oncology‐specific dosing recommendations. Personalized oncology care through integrated pharmacogenomics represents a unique multidisciplinary collaboration between oncologists, laboratory science, bioinformatics, pharmacists, clinical pharmacologists, and genetic counselors, among others. The authors posit that expanded consideration of germline genetic information can further transform the safe and effective practice of oncology in 2022 and beyond.
Integrating a community-based approach to non-communicable diseases care: a pilot programme in Bangladesh
Authors: Ariful Haque, Anne Cameron, Asadur Rahman, Nilima Mehta, Nayanjeet Chaudhury, Ariful Alam, Morseda Chowdhury, Adam Schwartz
Journal: The Lancet Global Health (2022)

As the threat of non-communicable diseases grows in Bangladesh, BRAC, in partnership with Medtronic, launched a pilot programme in early 2020 to leverage community health workers to improve the health outcomes of patients with hypertension and diabetes. This project builds off of BRAC's existing non-communicable disease programme, established in 2016, but incorporates patient-centred approaches to monitor and improve both patient compliance and outcomes.Activities included BRAC-run non-communicable disease centres to diagnose and treat patients with non-communicable diseases and specially trained community health workers to provide community-level care and strengthen referral linkages with NCD centres. BRAC also worked diligently to adapt its programming to the context of COVID-19, including equipping a subset of enrolled patients with machines to record their blood pressure and blood glucose levels at home with additional supervision by community health workers.Preliminary results were promising-on average, 90% of both home-based and clinic-based patients showed clinical improvements, and 91% were retained in care. About 98% of community health workers had on-time follow-up of patients with non-communicable diseases, showing routine compliance of care at the household level.Despite the pandemic, community health workers proved to be an effective tool in chronic disease management because the community trusts them and is receptive to their guidance, empowering health workers to deliver non-communicable disease care and promote lifestyle modifications. Contingent on further funding, BRAC will evaluate the effectiveness of this model in sustaining clinical outcomes and identifying pathways to scale across BRAC's large-scale health programme of over 40 000 community health workers.Medtronic (formerly known as Medtronic Foundation).
CULTURE-NEGATIVE INFECTIVE ENDOCARDITIS IN A PATIENT WITH A VALVE-IN-RING TRANSCATHETER MITRAL VALVE REPLACEMENT
Authors: Shamitha A. Manohar, Ahmed Ghoneem, Ammar Bhatti, Sardar H. Ijaz, Hoshang Farhad, Sonu Abraham, Gregory Smaroff, Sourbha S. Dani, Sherif Labib
Journal: Journal of the American College of Cardiology (2022)
SINGLE ACUTE MECHANICAL CIRCULATORY SUPPORT DEVICE USE IS ASSOCIATED WITH REDUCED MORTALITY COMPARED TO MULTI-AGENT DRUG THERAPY FOR CARDIOGENIC SHOCK DUE TO ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI-CS): AN ANALYSIS OF THE CARDIOGENIC SHOCK WORKING GROUP REGISTRY
Authors: Navin Kapur, Borui Li, Yijing Zhang, Katherine Thayer, Arthur R. Garan, Jaime Hernandez-Montfort, Manreet Kanwar, Shashank S. Sinha, Claudius Mahr, Jacob Abraham, Gavin W. Hickey, Sandeep Nathan, Andrew D. Schwartzman, Bram Geller, Esther E. Vorovich, Daniel Burkhoff
Journal: Journal of the American College of Cardiology (2022)
CONTINUOUS MECHANICAL ASPIRATION FOR THROMBECTOMY PRIOR TO PCI IN HIGH THROMBUS BURDEN STEMI PATIENTS: A SUBSET ANALYSIS OF THE CHEETAH STUDY
Authors: Santhosh Jay Mathews, Sahil A. Parikh, Jeffrey W. Chambers, David C. Metzger, Magdi G.H. Ghali, Willis Wu
Journal: Journal of the American College of Cardiology (2022)
HSR22-145: Pembrolizumab Plus Chemotherapy for First-Line Treatment of Advanced Triple-Negative Breast Cancer – A Network Meta-Analysis
Authors: Amin Haiderali, Min Huang, Wilbur Pan, Grace Fox, Dylan Maciel, Andrew Frederickson
Journal: Journal of the National Comprehensive Cancer Network (2022)

"HSR22-145: Pembrolizumab Plus Chemotherapy for First-Line Treatment of Advanced Triple-Negative Breast Cancer – A Network Meta-Analysis" published on 31 Mar 2022 by National Comprehensive Cancer Network.
IMPACT OF SACUBITRIL/VALSARTAN ON CLINICAL OUTCOMES IN HEART FAILURE USING REAL-WORLD DATA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Alaa Rahhal, Mohamed Kasem, Bassant Orabi, Safae Abuyousef, Fatima Hamou, Ahmed Mahfouz, Sumaya Alyafei, Emad Ahmed Hassan
Journal: Journal of the American College of Cardiology (2022)
ANTITHROMBOTIC TREATMENT AFTER THE LEFT ATRIAL APPENDAGE OCCLUSION: IMPACT ON CLINICAL OUTCOMES IN RUSSIAN PROSPECTIVE REGISTRY
Authors: Irina Merkulova, Dmitriy Pevzner, Yulia Rytova, Olga Shakhmatova, Eric Avetisyan, Evgeny Merkulov
Journal: Journal of the American College of Cardiology (2022)
Associations of long-term physical activity trajectories with coronary artery calcium progression and cardiovascular disease events: results from the CARDIA study
Authors: Jing-Wei Gao, Qing-Yun Hao, Liu-Yi Lu, Jia-Jin Han, Fei-Fei Huang, Dominique A. Vuitton, Jing-Feng Wang, Shao-Ling Zhang, Pin-Ming Liu
Journal: British Journal of Sports Medicine (2022)

The study aimed to assess the associations of physical activity (PA) trajectories across a 25-year span with coronary artery calcium (CAC) progression, and subsequent risk of cardiovascular disease (CVD) events.We included 2497 participants from the Coronary Artery Disease Risk Development in Young Adults study who had computed tomography-assessment of CAC at baseline (year 15: 2000-2001) and follow-up (year 20 or 25) and at least three measures of PA from year 0 to year 25. Long-term PA trajectories were determined by latent class modelling using a validated questionnaire.Among the included participants, 1120 (44.9%) were men, 1418 (56.8%) were white, and the mean (SD) age was 40.4 (3.6) years. We identified three distinct PA trajectories based on PA average levels and change patterns: low (below PA guidelines, n=1332; 53.3%); moderate (meeting and slightly over PA guidelines, n=919; 36.8%) and high (about three times PA guidelines or more, n=246; 9.9%). During a mean (SD) follow-up of 8.9 (2.1) years, 640 (25.6%) participants had CAC progression. Participants in the high PA trajectory group had a higher risk of CAC progression than those in the low PA trajectory group after adjustment for traditional cardiovascular risk factors (HR 1.51; 95% CI 1.18 to 1.94). However, high PA trajectory was not associated with an increased risk of incident CVD events (HR 1.01; 95% CI 0.44 to 2.31) and the incidence of CVD events in participants with CAC progression was similar across all three PA trajectory groups (p=0.736).Long-term PA about three times the guidelines or more is independently associated with CAC progression; however, no additional risk of incident CVD events could be detected.
Targeting the Adaptive Immune System in Depression: Focus on T Helper 17 Cells
Authors: Eléonore Beurel, Eva M. Medina-Rodriguez, Richard S. Jope
Journal: Pharmacological Reviews (2022)

There is a vital need to understand mechanisms contributing to susceptibility to depression to improve treatments for the 11% of Americans who currently suffer from this debilitating disease. The adaptive immune system, comprising T and B cells, has emerged as a potential contributor to depression, as demonstrated in the context of lymphopenic mice. Overall, patients with depression have reduced circulating T and regulatory B cells, "immunosuppressed" T cells, and alterations in the relative abundance of T cell subtypes. T helper (Th) cells have the capacity to differentiate to various lineages depending on the cytokine environment, antigen stimulation, and costimulation. Regulatory T cells are decreased, and the Th1/Th2 ratio and the Th17 cells are increased in patients with depression. Evidence for changes in each Th lineage has been reported to some extent in patients with depression. However, the evidence is strongest for the association of depression with changes in Th17 cells. Th17 cells produce the inflammatory cytokine interleukin (IL)-17A, and the discovery of Th17 cell involvement in depression evolved from the well established link that IL-6, which is required for Th17 cell differentiation, contributes to the onset, and possibly maintenance, of depression. One intriguing action of Th17 cells is their participation in the gut-brain axis to mediate stress responses. Although the mechanisms of action of Th17 cells in depression remain unclear, neutralization of IL-17A by anti-IL-17A antibodies, blocking stress-induced production, or release of gut Th17 cells represent feasible therapeutic approaches and might provide a new avenue to improve depression symptoms. <h3>Significance Statement</h3> Th17 cells appear as a promising therapeutic target for depression, for which efficacious therapeutic options are limited. The use of neutralizing antibodies targeting Th17 cells has provided encouraging results in depressed patients with comorbid autoimmune diseases.
Acute colonic diverticular haemorrhage: to band or clip?
Authors: Tony C. Tham
Journal: Endoscopy (2022)

There are several endoscopic options to stop acute hemorrhage from colonic diverticula, such as adrenaline injection, band ligation, endoloops, clips (both through the scope [TTS] and over the scope [OTS]), thermal therapy for example bipolar coagulation or argon plasma coagulation, and hemostatic powder. All have been reported to be effective in case reports and case series, although no head-to-head randomized controlled trials or systematic reviews of endoscopic therapies in this setting have been reported.
ALTERATIONS IN METABOLISM AFTER PLACEMENT OF A LEFT VENTRICULAR ASSIST DEVICE IN HEART FAILURE PATIENTS
Authors: James Baleja, Samuel Potash, Tatiana Mendez, Janis Breeze, Didjana Celkupa, Judit Laidlaw, Norma Terrin, Gordon Huggins, Amanda Vest
Journal: Journal of the American College of Cardiology (2022)
Abstract PD5-09: Work status changes and associated factors in a nation-wide sample of 1324 Norwegian long-term breast cancer survivors
Authors: Synne-Kristin Hoffart Bøhn, Kathrine Vandraas, Cecilie E Kiserud, Alv A Dahl, Marianne Ewertz, Hanne Cathrine Lie, Ragnhild Falk, Kristin Valborg Reinertsen
Journal: Cancer Research (2022)

Abstract Background: Little is known about work participation in breast cancer survivors (BCSs) beyond two years after diagnosis. This study aims to report work status at diagnosis and at eight years post-diagnosis in a nation-wide sample of BCSs, investigate factors associated with reduced work status, and report on self-perceived reasons for reduced work status or disability pension. Material and Methods: Women diagnosed with stage I-III BC at the age of 20-65 years in 2011 or 2012 were invited to participate (n=2,803), of which 49 % (n=1361) responded. The response rate was 49 % (n=1361). A final sample of 1324 BCSs with complete questionnaire information regarding work status were included in the present study. Logistic regression analyses were applied to identify factors associated with reduced work status. Results At diagnosis, 78% (n=1038) of the BCSs were in paid work, 12% received disability pension and 4 % held early retirement. At survey, 42% of the BCSs were in paid work, 26% held disability pension and 28% were retired. Of the 845 survivors who were in paid work at diagnosis and within working age at survey, 63% maintained their work status, while 37% reduced their work status. Living with children (OR 0.4, p=.007), older age (OR 1.2, p&amp;lt;.001), chemotherapy (OR 2.9, p=.013), three or more comorbid conditions (OR 2.2, p=.016), higher level of fatigue (OR 1.02, p&amp;lt;.001), symptoms of cognitive dysfunction (OR 0.9, p=.038) and higher degree of neuroticism (OR 1.2, p=.012) were associated with reduced work status. BC, complaints and late effects after BC were reported as the main or partial reason for reduced work status and disability. Conclusion Almost two thirds of BCSs in working age who were in paid work at diagnosis remained in the paid work force eight years later. Individual characteristics and various health complaints including fatigue end cognitive dysfunction were associated with reduced work status from diagnosis to survey. Evaluation and treatment of these conditions are warranted, with the ultimate aim of improving work maintenance in long-term BCSs. Citation Format: Synne-Kristin Hoffart Bøhn, Kathrine Vandraas, Cecilie E Kiserud, Alv A Dahl, Marianne Ewertz, Hanne Cathrine Lie, Ragnhild Falk, Kristin Valborg Reinertsen. Work status changes and associated factors in a nation-wide sample of 1324 Norwegian long-term breast cancer survivors [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD5-09.
hnRNPL-activated circANKRD42 back-splicing and circANKRD42-mediated crosstalk of mechanical stiffness and biochemical signal in lung fibrosis
Authors: Pan Xu, Jinjin Zhang, Meirong Wang, Bo Liu, Rongrong Li, Hongbo Li, Nailiang Zhai, Weili Liu, Changjun Lv, Xiaodong Song
Journal: Molecular Therapy (2022)

Increasing circular RNAs (circRNAs) are involved in the progression of idiopathic pulmonary fibrosis (IPF). However, circRNA biogenesis and circRNA-mediated crosstalk between mechanical stiffness and biochemical signals in IPF remain obscure. In this study, a novel circRNA-ankyrin repeat domain 42 (ANKRD42) from peripheral blood of patients with IPF, which participated in pulmonary fibrosis through the close communication of mechanical stiffness and biochemical signals, was identified. Mechanistic studies revealed that the heterogeneous nuclear ribonucleoprotein L (hnRNP L) activated the circANKRD42 reverse splicing biogenesis. The biogenetic circANKRD42 sponged miR-324-5p to promote the AJUBA expression, which blocked the binding between phosphorylated yes-associated protein 1 (YAP1) and large tumor suppressor kinase 1/2 (LATS1/2), leading to increased YAP1 entering the nucleus. circANKRD42 also sponged miR-136-5p to promote the YAP1 translation. Accumulating YAP1 in nucleus bound to TEAD, which initiated the transcription of genes related to mechanical stiffness. Finally, the therapeutic effect of circANKRD42 was evaluated in mice and the association between circANKRD42 and clinicopathological features was analyzed in IPF patients. Our findings supported that circANKRD42 is a promising biomarker and a potential therapeutic target related to cytoskeleton tension for IPF treatment. Increasing circular RNAs (circRNAs) are involved in the progression of idiopathic pulmonary fibrosis (IPF). However, circRNA biogenesis and circRNA-mediated crosstalk between mechanical stiffness and biochemical signals in IPF remain obscure. In this study, a novel circRNA-ankyrin repeat domain 42 (ANKRD42) from peripheral blood of patients with IPF, which participated in pulmonary fibrosis through the close communication of mechanical stiffness and biochemical signals, was identified. Mechanistic studies revealed that the heterogeneous nuclear ribonucleoprotein L (hnRNP L) activated the circANKRD42 reverse splicing biogenesis. The biogenetic circANKRD42 sponged miR-324-5p to promote the AJUBA expression, which blocked the binding between phosphorylated yes-associated protein 1 (YAP1) and large tumor suppressor kinase 1/2 (LATS1/2), leading to increased YAP1 entering the nucleus. circANKRD42 also sponged miR-136-5p to promote the YAP1 translation. Accumulating YAP1 in nucleus bound to TEAD, which initiated the transcription of genes related to mechanical stiffness. Finally, the therapeutic effect of circANKRD42 was evaluated in mice and the association between circANKRD42 and clinicopathological features was analyzed in IPF patients. Our findings supported that circANKRD42 is a promising biomarker and a potential therapeutic target related to cytoskeleton tension for IPF treatment.
FULMINANT MYOCARDITIS AS THE INITIAL PRESENTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: Jorge Sanchez-Nieto, Luis Antonio Jimenez Ruan, Enma Toledo, Clara E. Hernandez Orellana, Alejandra C. González Mira, José L. Briseño De la Cruz, Ricardo Pohls Vazquez, Leonardo D. Alcazar Flores, Gerardo Chacon Loyola, Soria Rodrigo
Journal: Journal of the American College of Cardiology (2022)
STRUCTURAL, INFLAMMATORY AND GENETIC CHANGES: THE PERFECT STORM FOR ARRHYTHMIC MITRAL VALVE PROLAPSE!
Authors: Ghaith Sharaf Dabbagh, Adnan Malik, Mahdi Veillet-Chowdhury, Edmond Obeng-Gyimah, Jefferson Lee, Gregory Fazio, Brian T. Schuler, C. Anwar A. Chahal
Journal: Journal of the American College of Cardiology (2022)
EVOLOCUMAB IN PEDIATRIC HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE HAUSER OPEN-LABEL EXTENSION STUDY
Authors: Raul Santos, Andrea Ruzza, G Kees Hovingh, Claudia Stefanutti, François Mach, Olivier Descamps, Jean Bergeron, Bei Wang, Andrea Bartuli, Paola Sabrina Buonuomo, Susanne Greber-Platzer, Ilse Luirink, Frederick J. Raal, John J.P. Kastelein, Albert Wiegman, Daniel Gaudet
Journal: Journal of the American College of Cardiology (2022)
BASELINE ELECTROCARDIOGRAPHIC ABNORMALITIES IN PRE-TREATMENT CANCER PATIENTS COMPARED WITH NON-CANCER GENERAL POPULATION OF SURGICAL PATIENTS: A PROPENSITY SCORE ANALYSIS
Authors: Alexandra Sarau, Lolita Golemi, Akash Sharma, Rajiv Varandani, Tochi M. Okwuosa
Journal: Journal of the American College of Cardiology (2022)
Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones
Authors: Jack A. Collora, Runxia Liu, Delia Pinto-Santini, Neal Ravindra, Carmela Ganoza, Javier R. Lama, Ricardo Alfaro, Jennifer Chiarella, Serena Spudich, Karam Mounzer, Pablo Tebas, Luis J. Montaner, David van Dijk, Ann Duerr, Ya-Chi Ho
Journal: Immunity (2022)
T‐cell receptor sequencing specifies psoriasis as a systemic and atopic dermatitis as a skin‐focused, allergen‐driven disease
Authors: Lennart M. Roesner, Ahmed K. Farag, Rebecca Pospich, Stephan Traidl, Thomas Werfel
Journal: Allergy (2022)

Abstract Background Atopic dermatitis (AD) and psoriasis represent two of the most common inflammatory skin diseases in developed countries. A hallmark of both diseases is T‐cell infiltration into the skin. However, it is still not clarified to what extent these infiltrating T cells are antigen‐specific skin‐homing T cells or unspecific heterogeneous bystander cells. Methods To elucidate this, T cells from lesional skin and from blood of 9 AD and 10 psoriasis patients were compared by receptor (TCR) sequencing. Therefore, peripheral blood mononuclear cells (PBMC) were cell‐sorted according to expression of the cutaneous leukocyte antigen (CLA) into skin‐homing (CLA + ) and non‐skin‐homing (CLA − ) subfractions. Aeroallergen‐specific T‐cell lines were grown from AD patients’ PBMC in parallel. Results Intra‐individual comparison of TCRB CDR3 regions revealed that clonally expanded T cells in skin lesions of both AD and psoriasis patients corresponded to skin‐homing circulating T cells. However, in psoriasis patients, these T‐cell clones were also detectable to a larger extent among CLA − circulating T cells. Up to 28% of infiltrating cells in AD skin were identified as allergen‐specific by overlapping TCR sequences. Conclusions Our data show that in line with the systemic nature of psoriasis, T‐cell clones that infiltrate psoriatic skin lesions do not exclusively possess skin‐homing ability and are therefore most probably specific to antigens that are not exclusively expressed or located in the skin. T cells driving AD skin inflammation appear to home nearly exclusively to the skin and are, to a certain extent, specific to aeroallergens.